DOCSLIB.ORG

FAMIS Formulary (Current)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

VIRGINIA PREMIER HEALTH PLAN FAMIS MEDICAID FORMULARY PLEASE NOTE: Check your benefit materials for the specific drugs covered and the copayments for your prescription drug program. For specific questions about your coverage, please call the phone number printed on your ID card. The list may not be all- inclusive. THIS LIST IS SUBJECT TO CHANGE. For the member: Generic medications contain the same active ingredients as their corresponding brand-name medications, although they may look different in color or shape. They have been FDA-approved under strict standards. For the physician: Please prescribe preferred products and allow generic substitutions when medically appropriate. Thank you. CURRENT AS OF 10/1/2021 Requirements/Limits AGE = Age limit requirement Custom = Drug has unique restrictions OTC = Over the Counter PA = Prior Authorization required QL = Quantity Level Limit lowercase italics = Generic Formulary SP = Specialty Drug. Preferred Specialty drugs Pharmacy will be listed if applicable UPPERCASE = Brand name Formulary Formulary Status ST = Step Therapy may apply to some or all drugs Formulary = Covered strengths of the drug Drug Name Formulary Status Requirements/Limits 1st relief spray external liquid 4-1 % Formulary OTC 1st tier unifine pentips 29g x 12mm , 31g x 5 mm , 31g x 6 Formulary OTC; QL (200 EA per 30 days) mm , 31g x 8 mm , 32g x 4 mm 1st tier unilet comfortouch Formulary OTC; QL (150 EA per 30 days) 4-N-1 EXTERNAL CREAM 1 % Formulary OTC 50+ adult eye health oral capsule Formulary OTC A & D ZINC OXIDE EXTERNAL CREAM Formulary OTC a thru z advanced oral tablet Formulary OTC a thru z advantage oral tablet Formulary OTC a thru z select oral tablet chewable Formulary OTC A+D CRACKED SKIN RELIEF EXTERNAL CREAM 2- Formulary OTC 0.13 % a1c test at-home in vitro kit Formulary OTC a-25 oral capsule 25000 unit Formulary OTC abacavir sulfate oral solution 20 mg/ml Formulary abacavir sulfate oral tablet 300 mg Formulary abacavir sulfate-lamivudine oral tablet 600-300 mg Formulary abacavir-lamivudine-zidovudine oral tablet 300-150-300 Formulary mg ABANATUSS PED ORAL LIQUID 15-0.5-6.25 MG/ML, Formulary OTC 60-2-25 MG/5ML ABATRACE ORAL CAPSULE Formulary OTC ABATREX ORAL TABLET 8-200-4-100-600 MG Formulary OTC ABATRON AF ORAL TABLET 150-1 MG Formulary OTC ABATRON ORAL LIQUID Formulary OTC ABATUSS DMX ORAL LIQUID 30-1-15 MG/5ML Formulary OTC ABILIFY MAINTENA INTRAMUSCULAR PREFILLED Formulary AGE (Min 18 Years) SYRINGE 300 MG, 400 MG ABILIFY MAINTENA INTRAMUSCULAR Formulary AGE (Min 18 Years) SUSPENSION RECONSTITUTED 300 MG, 400 MG ABILIFY MAINTENA INTRAMUSCULAR Formulary AGE (Min 18 Years) SUSPENSION RECONSTITUTED ER 300 MG, 400 MG ABILIFY MYCITE ORAL TABLET 10 MG, 15 MG, 2 Formulary PA MG, 20 MG, 30 MG, 5 MG abiraterone acetate oral tablet 250 mg Formulary ABRAXANE INTRAVENOUS SUSPENSION Formulary RECONSTITUTED 100 MG 1 Drug Name Formulary Status Requirements/Limits ABREVA EXTERNAL CREAM 10 % Formulary OTC acamprosate calcium oral tablet delayed release 333 mg Formulary acarbose oral tablet 100 mg, 25 mg, 50 mg Formulary ACCU-CHEK FASTCLIX LANCET KIT Formulary OTC ACCU-CHEK SOFT TOUCH LANCETS Formulary OTC; QL (150 EA per 30 days) ACCU-CHEK SOFTCLIX LANCETS Formulary OTC; QL (150 EA per 30 days) ACCUTANE ORAL CAPSULE 20 MG, 30 MG, 40 MG Formulary ACCUTREND CHOLESTEROL CONTROL IN VITRO Formulary OTC SOLUTION ACCUTREND CHOLESTEROL IN VITRO STRIP Formulary OTC ACCUTREND PLUS DEVICE Formulary OTC ACE AEROSOL CLOUD ENHANCER Formulary QL (2 EA per 365 days) ACE KNEE BRACE W/STABILIZERS Formulary OTC acebutolol hcl oral capsule 200 mg, 400 mg Formulary ACEROLA C 500 ORAL WAFER 500 MG Formulary OTC ACETA-GESIC ORAL TABLET 12.5-325 MG Formulary OTC acetaminophen extra strength oral liquid 500 mg/15ml Formulary OTC acetaminophen junior strength oral tablet dispersible 160 Formulary OTC mg acetaminophen oral liquid 160 mg/5ml Formulary OTC acetaminophen oral solution 160 mg/5ml Formulary OTC acetaminophen oral tablet 325 mg Formulary OTC acetaminophen rapid tabs child oral tablet dispersible 80 Formulary OTC mg acetaminophen rectal suppository 650 mg Formulary OTC acetaminophen-codeine #2 oral tablet 300-15 mg Formulary PA; QL (280 EA per 7 days) acetaminophen-codeine #3 oral tablet 300-30 mg Formulary PA; QL (140 EA per 7 days) acetaminophen-codeine #4 oral tablet 300-60 mg Formulary PA; QL (70 EA per 7 days) acetaminophen-codeine oral solution 120-12 mg/5ml Formulary PA; QL (1750 ML per 7 days) ACETASOL HC OTIC SOLUTION 2-1 % Formulary acetazolamide er oral capsule extended release 12 hour 500 Formulary mg acetazolamide oral tablet 250 mg Formulary acetic acid irrigation solution 0.25 % Formulary acetic acid otic solution 2 % Formulary acetylcysteine inhalation solution 10 %, 20 % Formulary ACID GONE ORAL SUSPENSION 95-358 MG/15ML Formulary OTC acid reducer maximum strength oral tablet 20 mg Formulary OTC acidophilus oral capsule Formulary OTC acidophilus probiotic oral tablet 10 mg Formulary OTC acidophilus/bifidus oral tablet chewable Formulary OTC acidophilus/citrus pectin oral tablet Formulary OTC acidophilus/pectin oral capsule Formulary OTC acitretin oral capsule 10 mg, 17.5 mg, 25 mg Formulary PA; QL (68 EA per 34 days) acne maximum strength external pad 2 % Formulary OTC 2 Drug Name Formulary Status Requirements/Limits acne medication 10 external gel 10 % Formulary OTC; AGE (Max 18 Years) acne medication 10 external lotion 10 % Formulary OTC; AGE (Max 18 Years) acne medication 5 external gel 5 % Formulary AGE (Max 18 Years) acne medication 5 external lotion 5 % Formulary OTC; AGE (Max 18 Years) acne treatment external bar 10 % Formulary OTC; AGE (Max 18 Years) ACNEFREE ACNE CLEARING SYSTEM EXTERNAL Formulary OTC KIT 2.5 & 3.7 % ACNEFREE SEVERE CLEARING SYST EXTERNAL Formulary OTC KIT 2.5 & 10 % ACT TOTAL CARE MOUTH/THROAT SOLUTION 0.05 Formulary OTC % ACTHIB INTRAMUSCULAR SOLUTION Formulary AGE (Min 19 Years) RECONSTITUTED ACTICARNITINE SF ORAL SOLUTION 1 GM/10ML Formulary OTC ACTICON ORAL SOLUTION 1-30 MG/5ML Formulary OTC ACTICON ORAL TABLET 2-60 MG Formulary OTC actidom dmx oral liquid 10-30-200 mg/5ml Formulary OTC ACTIDOSE WITH SORBITOL ORAL LIQUID 50 Formulary OTC GM/240ML actidose-aqua oral liquid 15 gm/72ml Formulary OTC ACTIFLOVIT EAR HEALTH ORAL TABLET Formulary OTC ACTIFOAM COLLAGEN SPONGE EXTERNAL Formulary acti-lance lite lancets 28g Formulary OTC; QL (150 EA per 30 days) acti-lance special lancets 17g Formulary OTC; QL (150 EA per 30 days) acti-lance universal 23g Formulary OTC; QL (150 EA per 30 days) ACTIMARIS WOUND EXTERNAL GEL Formulary OTC ACTIMMUNE SUBCUTANEOUS SOLUTION 2000000 Formulary UNIT/0.5ML ACTINEL ORAL LIQUID 30-15-200 MG/5ML Formulary OTC ACTISEP MOUTH/THROAT SOLUTION 2-0.5-0.1 % Formulary OTC ACTITROM ORAL CAPSULE Formulary OTC ACTIVE Q MAXIMUM STRENGTH ORAL CAPSULE Formulary OTC 300 MG ACTIVE Q ORAL SYRUP 100 MG/5ML Formulary OTC ACTIVE-Q EXTRA STRENGTH ORAL CAPSULE 200 Formulary OTC MG ACTIVE-Q ORAL CAPSULE 200-30 MG Formulary OTC ACTIVITE EC ORAL TABLET 1 MG Formulary OTC ACTIVON ARTHRITIS ULTRA ST EXTERNAL STICK Formulary OTC 0.028-4.574 % acyclovir external ointment 5 % Formulary acyclovir oral capsule 200 mg Formulary acyclovir oral suspension 200 mg/5ml Formulary acyclovir oral tablet 400 mg, 800 mg Formulary ADACEL INTRAMUSCULAR SUSPENSION 5-2-15.5 Formulary LF-MCG/0.5 3 Drug Name Formulary Status Requirements/Limits ADAGEN INTRAMUSCULAR SOLUTION 250 Formulary PA UNIT/ML adapalene external cream 0.1 % Formulary AGE (Max 18 Years) adapalene external gel 0.1 %, 0.3 % Formulary AGE (Max 18 Years) adefovir dipivoxil oral tablet 10 mg Formulary adhesive bandages sheer Formulary OTC adjustable lancing device Formulary OTC; QL (1 EA per 365 days) ADMELOG SOLOSTAR SUBCUTANEOUS SOLUTION Formulary PEN-INJECTOR 100 UNIT/ML ADMELOG SUBCUTANEOUS SOLUTION 100 Formulary UNIT/ML ADRENAL C FORMULA ORAL TABLET Formulary ADRENALIN INJECTION SOLUTION 1 MG/ML, 30 Formulary MG/30ML ADRUCIL INTRAVENOUS SOLUTION 2.5 GM/50ML, 5 Formulary GM/100ML, 500 MG/10ML ADULT ACNOMEL EXTERNAL CREAM 2-8 % Formulary OTC adult gummy oral tablet chewable Formulary OTC adult mask device Formulary QL (2 EA per 365 days) adult wash cloths with aloe external 3 % Formulary OTC adult-lock weekly pill remind Formulary OTC advanced acne wash external liquid extended release 4.4 % Formulary OTC ADVANCED CALCIUM/D/MAGNESIUM ORAL Formulary OTC TABLET advanced hand sanitizer external liquid 70 % Formulary OTC advanced lubricant ophthalmic solution 0.05-1 % Formulary OTC ADVIL ALLERGY & CONGESTION ORAL TABLET 4- Formulary OTC 10-200 MG ADVIL ALLERGY SINUS ORAL TABLET 2-30-200 MG Formulary OTC ADVIL COLD & SINUS LIQUI-GELS ORAL CAPSULE Formulary OTC 30-200 MG ADVIL COLD/SINUS ORAL TABLET 30-200 MG Formulary OTC ADVIL ORAL CAPSULE 200 MG Formulary OTC ADVIL ORAL TABLET 200 MG Formulary OTC ADVIL PM ORAL CAPSULE 200-25 MG Formulary OTC ADVIL PM ORAL TABLET 200-38 MG Formulary OTC ADVIL SINUS CONGESTION & PAIN ORAL TABLET Formulary OTC 10-200 MG ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.5 ML Formulary OTC 29G X 1/2" 0.5 ML ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.3 ML Formulary OTC 30G X 5/16" 0.3 ML ADVOCATE INSULIN SYRINGE 30G X 5/16" 1 ML 30G Formulary OTC X 5/16" 1 ML ADVOCATE INSULIN SYRINGE 31G X 5/16" 1 ML 31G Formulary OTC X 5/16" 1 ML AEROCHAMBER MINI CHAMBER DEVICE Formulary QL (2 EA per 365 days) 4 Drug Name Formulary Status Requirements/Limits AFLURIA INTRAMUSCULAR SUSPENSION Formulary AGE (Min 19 Years) AFLURIA PRESERVATIVE FREE INTRAMUSCULAR Formulary AGE (Min 19 Years) SUSPENSION PREFILLED SYRINGE 0.5 ML AFLURIA QUADRIVALENT
Recommended publications
  • Camphor Revisited: Focus on Toxicity

    Camphor Revisited: Focus on Toxicity

    Camphor Revisited: Focus on Toxicity Committee on Drugs This commentary updates a previous AAP state- TABLE. List of Camphor-Containing Products ment developed by the Committee on Drugs con- Product % of Camphor cerning camphor.1 The original commentary re- Absorbine Arthritic Pain Lotion 10 flected the level of concern among pediatric Act-On Rub Lotion 1.5 practitioners and poison centers about the toxicity of Anabaim Lotion 3 camphor. Since the original statement, the Food and Aveeno Anti-Itch Conc. Lotion 0.3 t Drug Administration (FDA) has recognized camphor Avalgesic Banaig Muscle Pain Reliever 2 as a safe and effective topical antitussive, analgesic, Bangesic t anesthetic, and antipruritic agent.2 Following the ap- Ben Gay Children’s Vaporizing Rub 5 proval process in 1983, the FDA required that the Betuline Lotion t concentration of camphor in products not exceed Campho-phemque First Aid Gel 10.8 Campho-phenique Uquid 10.85 11%.2 Fligher concentrations were not more effective Campho-phemque Powder 4.375 and could cause more serious adverse reactions if Counterpain Rub t accidentally ingested. Most reported camphor-re- Deep Down Rub 0.5 lated fatalities involved agents containing a concen- Dencorub Cream Dermal Rub t tration greater than 11%. Dermolin Liniment t Ingestion of potentially toxic substances by chil- Emul-O-Balm 1.1 dren is related to the availabffity of a product in their Heet Lotion 3 3.6 environment. Camphor remains widely available Heat Spray Minit-Rub 3.5 (Table). The toxicity of camphor when inappropri- Mollifene Ear Drops t ately used is well documented.6 Ingestion is the Musterole Regular 4 most common route of potentially toxic exposure, Panalgesic 3 with rapid onset of toxic effects.
  • Absorbine Veterinary Liniment for Horses

    Absorbine Veterinary Liniment for Horses

    Doc# 03.287 Ver. 11 SAFETY DATA SHEET ABSORBINE® VETERINARY LINIMENT SECTION 1 - PRODUCT AND COMPANY IDENTIFICATION 1.1 Trade Name (as labeled): Absorbine® Veterinary Liniment Synonyms: N/A CAS No: Mixture 1.2 Product Use: Soothes sore muscles and stiff joints 1.3 Company Name: W.F. Young Company Address: 302 Benton Dr Company Address Cont: East Longmeadow, MA 01028 Business Phone: ( 413) 526-9999 Website: www.wfyoung.com 1.4 Emergency Telephone Number: (413) 526-9999 Date of Current Revision: January 17, 2017 Date of Last Revision: August 7, 2015 SECTION 2 - HAZARD IDENTIFICATION EMERGENCY OVERVIEW: This product is a green thin liquid with an acetone odor. Health Hazards: May cause skin, eye, and respiratory system irritation. Flammabilit Hazards: This product is a flammable liquid with a flash point over 20°F (-6. 7°C). Reactivit Hazards: None. Environmental Hazards: The environmental effectsof this product have not been investigated, however release may cause long term adverse environmental effects. US DOT Symbols: EU and GHS Symbols: Signal Word: Danger! 2.1 CLASSIFICATION OF SUBSTANCE OR MIXTURE IN ACCORDANCE WITH 29 CFR 1200 (OSHA HCSl AND THE EUROPEAN UNION DIRECTIVES: This product does meet the definition of a hazardous substance or preparation as defined by 29 CFR 1910. 1200 or the European Union Council Directives 67 /548/EEC, 1999/45/EC, 1272/2008/EC and subsequent Directives. EU HAZARD CLASSIFICATIONOF INGREDIENTS PER DIRECTIVE 1272/2008/EC: IndexNumber: EC# 201-939-0 This substance is not classified in the AnnexVI of Directive 67/548/EEC EC# 200-662-2 This substance is classified in the AnnexVI of Directive 67/548/EEC Index# 606-001-00-8 Substances not listed either individually or in group entries must be self classified.
  • Veterinary Dairy Spray Liniment by Dan Leiterman

    Veterinary Dairy Spray Liniment by Dan Leiterman

    1-888-376-6777 www.crystalcreeknatural.com December 2011 Introducing - Veterinary Dairy Spray Liniment By Dan Leiterman Crystal Creek is pleased to announce the addition of the new Veterinary Dairy Spray Liniment Features: Veterinary Dairy Spray Liniment • Available In A 24 oz. Spray Bottle Or A One Gallon (128 oz.) Refill Jug (VDSL) to our family of liniments (Veterinary Dairy Liniment and • A High Performance – Strong Relief Formula: Lini-Rub). Veterinary Dairy Spray Liniment provides the same ‘Contrast Therapy’ Warming and Cooling excellent performance as the original Analgesic Pain Relief rub-on Veterinary Dairy Liniment, only now with the convenience of a Anti-Inflammatory spray-on application. Anti-Microbial Skin Support – an aloe vera based formula Veterinary Dairy Spray Liniment is a powerful analgesic that combines • New Color For Lingering Identification Of Sprayed Animals the proven benefits of both warming and cooling ‘contrast therapy’ for • Meets National Organic Program Standards – challenged muscle tissue and edema Consider For Organic Use relief. The deep penetrating warmth soothes and supports proper • Economical To Use: circulation, while the lingering Retail Price coolness helps to reduce edema and inflammation of muscle tissue. 24 oz. Spray Bottle $29.95 / bottle If you prefer a spray-on liniment, Case Price (6 bottles/case) try Veterinary Dairy Spray Liniment and see the difference – it is stronger $28.95 / bottle and is better priced than the One Gallon Jug competition. If you prefer rub-on $134.00 / gallon liniments, try the Veterinary Dairy Case Price (4 gallons/case) Liniment (a white cream based $128.00 / gallon liniment) or the Crystal Creek Lini- Rub (an oil based liniment) and experience their excellent performance.
  • In This Section

    In This Section

    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
  • Safety Data Sheet

    Safety Data Sheet

    First issue: September 17, 2009 Revision date: October 27, 2014 SDS No. 007.636 Version: 5 SAFETY DATA SHEET In accordance with OSHA’s Hazard Communication Standard 29 CFR §1910.1200 SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1. Product identifier: Absorbine® Veterinary Liniment Gel 1.2. Relevant identified uses of the substance or mixture and uses advised against Topical Analgesic 1.3. Details of the supplier of the safety data sheet Manufacturer/Supplier: W. F. Young, Inc. 302 Benton Drive East Longmeadow, MA 01028 Telephone number for information: 413 526 9999 E-mail: [email protected] 1.4. Emergency telephone number 413 526 9999 SECTION 2: HAZARDS IDENTIFICATION 2.1. Classification of the mixture F, Xn, Xi R10, 22, 43 2.2. Label elements Flammable Keep out of the reach of children Harmful if swallowed May product an allergic reaction 2.3. Other hazards Inhalation of vapors can cause anesthetic effect. Page 1 of 8 First issue: September 17, 2009 Revision date: October 27, 2014 SDS No. 007.636 Version: 5 SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS 3.2. Mixtures Hazardous ingredients information Component CAS Nr. EINECS / Amount DSD DSD ELINCS (%) Hazard R-Phrases Symbol Ethanola,denatured 64-17-5 200-578-6 40 - 70 F R11 Menthol 89-78-1 201-939-0 4 Choroxylenol 88-04-0 201-793-8 0.5 Xi R43 Spearmint Oil 8008-79-5 Not classified 0.5-1.0 Xi R43 Propylene Glycola 57-55-6 200-338-0 1 - 5 Other Components: Remaining components of this alcoholic mixture are proprietary, non-hazardous and/or are present at concentrations below reportable limits.
  • Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000

    Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000

    GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
  • We Have Some Trouble with Special Characters and Displaying Monographs. 22.09.2018 ATC Code: D04AB01 Classification

    We Have Some Trouble with Special Characters and Displaying Monographs. 22.09.2018 ATC Code: D04AB01 Classification

    We have some trouble with special characters and displaying monographs. 22.09.2018 ATC code: D04AB01 Classification: PNP - Probably not porphyrinogenic Substance: Lidocaine Rationale for risk classification: Lidocaine is metabolized by CYP1A2, with only a minor contribution from CYP 3A4. Lidocaine is not listed as an inducer or as a mechanism-based inhibitor of CYP enzymes, nor is there any evidence of lidocaine capacity for Cyp-inhibition in clinical use. Lidocaine is reported as used uneventfully by 68 patients, and thus strong clinical evidence points to lidocaine as probably not porphyrinogenic. The systemic availability of lidocaine after restricted dermal use is usually low. Chemical description: Lidocaine hydrochloride is an amide derivative of diethyl amino acetic acid. Lidocaine has a lipophilic aromatic ring attached to a hydrophilic amino group by an amide linkage. Therapeutic characteristics: Lidocaine is a local anesthetic. In dermatological preparations lidocaine is used for the symptomatic relief of pain, itching or irritation of the skin or mucous membranes. It can be administered in topical formulations like ointment, gel or liniment for conditions like superficial skin wounds, insect bites, burns, herpes genitalis, and anal lesions or before various medical procedures. Extent of hepatic exposure: The plasma concentration of lidocaine is dependent on dose, administration method and vascularity of the site of administration. Whether the site of application has a traumatised or intact surface will also affect the absorption and systemic availability of the drug. Lidocaine is readily absorbed from mucous membranes and through damaged skin The hepatic exposure of lidocaine after restricted dermal use is probably not significant.. Systemic plasma concentrations after repeted anorectal administration of 5 % lidocaine ointment was found to be below uM (Zimmermann 2007).
  • Today's Research Tomorrow's Cure

    Today's Research Tomorrow's Cure

    2018 Heart Research Institute Annual Review Accelerating Research Tomorrow’s cure Tomorrow’s Today’s research Today’s 2018 Heart Research Institute Annual Review Hello Future Accelerating 2018 Heart Research Institute Annual Review Research ACCELERATING Discoveries into therapies Knowledge into prevention Breakthroughs into cures Students into leaders Collaborations into partnerships 4 2018 Heart Research Institute Annual Review Inspiring Leaders 2018 Heart Research Institute Annual Review CONTENTS 06 HRI in 2018 08 Chairman’s Report 2018 10 Director of Cardiovascular Research Report 12 2018 Research and Media Highlights 16 Applied Materials Group 18 Atherosclerosis and Vascular Remodelling Group 20 Cardiac Imaging Group 22 Cardiometabolic Disease Group 24 Cardiovascular Medical Devices Group 26 Cell Therapeutics Group 28 Clinical Research Group 30 Haematology Research Group 32 Heart Rhythm and Stroke Prevention Group 34 High Blood Pressure Group 36 Thrombosis Group 38 Vascular Complications Group 40 Vascular Immunology Group 42 Inflammation and Fibrosis Research 44 PhD Students 45 Select Prizes and Awards 46 Select Conferences and Presentations 50 Select Publications 56 Board of Governors 59 International Board of Governors 60 Members of the Institute 62 Fundraising Report 66 Operations Report 6 2018 Heart Research Institute Annual Review The mission of the Heart Research Institute (HRI) is to prevent death and suffering from cardiovascular disease through an understanding of the biological processes that cause atherosclerosis and thrombosis, the major underlying causes of most heart attacks and strokes. 20 18 SHORT TERM LONG TERM The major short-term focus of our research There are four long-term objectives is to understand the development and for our research: progression of atherothrombotic conditions • To investigate mechanisms in which the arteries are narrowed and contributing to the pathogenesis restricted due to a build-up of fatty of cardiovascular disease.
  • Building Innovation, Performance and Trust

    Building Innovation, Performance and Trust

    Building Innovation, Performance and Trust Emma Walmsley, CEO Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements. Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate.
  • Dosage Form FDA Data Element Number

    Dosage Form FDA Data Element Number

    Home Drugs Development & Approval Process (Drugs) Forms & Submission Requirements Electronic Submissions to CDER Data Standards Manual (monographs) Drugs Dosage Form FDA Data Element Number. None. CDER Data Element Number. C-DRG-00201 Data Element Name. Dosage Form. Data Element OID: 2.16.840.1.113883.3.26.1.1.2 Data Element NCI Concept ID: C42636 Version Number. 008 Description. This standard provides for all drug dosage forms. The granularity of data often requires that more specific dosage form terms be stored in automated databases than are represented in publications. These dosage form terms are available not only for use in databases that track approved drug products, but also for drug products such as: those that have not been approved, investigational drug products, homeopathic drug products, biologic products, veterinary drug products, and bulk drug products. A ‘use restrictions’ column is being added to help identify where a particular dosage form set or subset should be used (a=CDER Databases, b=NDC Directory, c=Orange Book). The definitions for Lotion, Cream, Ointment, and Paste were revised on June 21, 2006 to include information that would assist the user in differentiating between these dosage forms. These changes were the result of discussions during an FDA Advisory Committee with an open public forum, scientific studies that were published in refereed pharmaceutical journals, and internal discussions by Agency personnel, including the usual adherence to the criteria that are specified in MaPP 7600.4. A 1999 Food and Drug Administration Draft Guidance for Industry states: "A dosage form is the way of identifying the drug in its physical form.
  • Hinkson Creek Comprehensive Chemical Analysis Proposal

    Hinkson Creek Comprehensive Chemical Analysis Proposal

    UNITED STATES GOVERNMENT memorandum DATE: August 29, 2019 REPLY TO ATTN OF: David Alvarez, USGS, 573-441-2970, [email protected] SUBJECT: Cost estimate for the analysis of water and sediment samples from Hinkson Creek TO: Lynne Hooper, Boone County Resource Management, [email protected] Investigation of continued causes of impairment in Hinkson Creek is of interest to the Hinkson Creek Science Team. Some work has been done looking at basic water quality parameters, but little data exists looking at organic and inorganic contaminants which may be related to increased urbanization in the watershed. The Environmental Chemistry Branch was asked to develop a sampling plan which includes potential indicator chemicals that may indicate an increased contaminant loading into the Creek. Below is an estimate for the chemical analysis of water and sediment samples from Hinkson Creek. The costs below represent totals for the sampling at 5 sites each during an upcoming Fall and Spring season. Options for both water and sediment analyzes are included. Proposed chemicals to be investigated include: a suite of metals typical of urban environments, current use pesticides (CUP) related to agriculture, wastewater indicators (WI), polycyclic aromatic hydrocarbons (PAHs), organochlorine pesticides, polychlorinated biphenyls (total PCBs), and polybrominated diphenyl ether (PBDE) flame retardants. A tentative list of analytes is provided as an attachment to this memo. In addition to the specific chemical analyses, a screen for total estrogenicity of chemicals will be run using the in vitro yeast estrogen screen (YES). The YES assay is a cell-based assay where estrogens or estrogen-mimicking chemicals bind to an estrogen receptor which can be measured.
  • Pharmaceutical Compounding and Dispensing Sample Chapter

    Pharmaceutical Compounding and Dispensing Sample Chapter

    Copyright Pharmaceutical Press www.pharmpress.com 6 Solutions Introduction and overview 101 Gargles and mouthwashes 105 General principles of solution preparation 103 Enemas and douches 105 Solubility 103 External solutions 105 Stability 103 Lotions 105 General method 103 Liniments 105 Oral solutions 104 Applications 105 Elixirs 104 Collodions 106 Linctuses 105 Worked examples 106 Syrups 105 Summary of essential principles relating to solutions 112 Mixtures 105 Packaging 112 Draughts 105 Discard dates 112 Spirits 105 Labelling 113 Paediatric drops 105 Introduction and overview Essentially a solution is a homogeneous liquid preparation that contains one or more dissolved med- Solutions are one of the oldest dosage forms used in the icaments. Since, by definition, active ingredients are treatment of patients and afford rapid and high dissolved within the vehicle, uniform doses by volume absorption of soluble medicinal products. Therefore, may be obtained without any need to shake the for- the compounding of solutions retains an important mulation. This is an advantage over some other for- place in therapeutics today. Owing to the simplicity mulation types (e.g. suspensions, see Chapter 7). and hence the speed of preparation of an ad hoc for- In general, water is chosen as the vehicle in which mulation, they are of particular use for individuals medicaments are dissolved, as it is non-toxic, non- who have difficulty in swallowing solid dosage forms irritant, tasteless, relatively cheap, and many drugs (for example paediatric, geriatric, intensive care and are water soluble. Problems may be encountered psychiatric patients), where compliance needs to be where active drugs are not particularly water soluble checked on administration (for example in prisons or or suffer from hydrolysis in aqueous solution.